VIPR1: A Potential Drug Target for Neurological Disorders (G7433)
VIPR1: A Potential Drug Target for Neurological Disorders
VIPR1 (Periandrocal commonly known as PACAP-R2) is a phosphatidylserine (PS) protein that plays an important biological role in the nervous system. Loss of VIPR1 can lead to a variety of neurodevelopmental and behavioral problems, including autism, Parkinson's disease, and Alzheimer's disease.
The molecular structure of VIPR1 is different from other PS proteins in the nervous system. It has two structural domains: N-terminal 伪-helix and C-terminal 尾-coil. The N-terminal 伪-helix is 鈥嬧?媋 secondary structure that forms an 伪-helix at the N-terminus of the protein. The C-terminal 尾-curl is a tertiary structure that forms a 尾-curl at the C-terminus of the protein. In addition, the C-terminus of VIPR1 also contains a hydrophobic tail, whose function is being studied in depth.
The function of VIPR1 in the nervous system is achieved by regulating the excitability of neurons. It is a negative regulator that can inhibit the over-excitation of neurons, thereby maintaining the normal activity state of neurons. In patients with Parkinson's disease, loss of VIPR1 causes neuronal hyperexcitability, leading to movement disorders and muscle stiffness.
Loss of VIPR1 also affects neuronal survival. Studies have shown that the loss of VIPR1 can lead to neuronal apoptosis and increase the degree of neuronal damage. Therefore, VIPR1 is also regarded as a biomarker of neuronal damage and has high clinical significance.
In addition to its biological role in the nervous system, VIPR1 is also widely used in drug development. Due to its negative regulatory role in the nervous system, VIPR1 is considered a potential drug target. Currently, VIPR1 has been used to treat a variety of neurological diseases, including autism, Parkinson's disease and Alzheimer's disease.
As a drug target, VIPR1 has important clinical significance. Future research will continue to further study the biological functions of VIPR1 and its application value in drug development.
Protein Name: Vasoactive Intestinal Peptide Receptor 1
Functions: This is a receptor for VIP. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. The affinity is VIP = PACAP-27 > PACAP-38
More Common Targets
VIPR1-AS1 | VIPR2 | VIRMA | VIT | VKORC1 | VKORC1L1 | VLDLR | VLDLR-AS1 | VMA21 | VMAC | VMO1 | VMP1 | VN1R1 | VN1R101P | VN1R108P | VN1R10P | VN1R11P | VN1R12P | VN1R17P | VN1R18P | VN1R2 | VN1R4 | VN1R46P | VN1R5 | VN1R82P | VN1R91P | VN1R96P | VN2R11P | VN2R1P | VN2R3P | VNN1 | VNN2 | VNN3P | Voltage-dependent anion channels (Porins) | Voltage-dependent calcium channel gamma subunit | Voltage-gated K(v) channel | Voltage-Gated Sodium Channel Complex | Volume-Regulated Anion Channel (VRAC) | VOPP1 | VOR Complex | VPREB1 | VPREB3 | VPS11 | VPS13A | VPS13A-AS1 | VPS13B | VPS13C | VPS13C-DT | VPS13D | VPS16 | VPS18 | VPS25 | VPS26A | VPS26AP1 | VPS26B | VPS26C | VPS28 | VPS29 | VPS33A | VPS33B | VPS35 | VPS35L | VPS36 | VPS37A | VPS37B | VPS37C | VPS37D | VPS39 | VPS41 | VPS45 | VPS4A | VPS4B | VPS50 | VPS51 | VPS51P8 | VPS52 | VPS53 | VPS54 | VPS72 | VPS8 | VPS9D1 | VPS9D1-AS1 | VRK1 | VRK2 | VRK3 | VRTN | VSIG1 | VSIG10 | VSIG10L | VSIG10L2 | VSIG2 | VSIG4 | VSIG8 | VSIR | VSNL1 | VSTM1 | VSTM2A | VSTM2A-OT1 | VSTM2B | VSTM2B-DT